The promise of stem cell-based therapy for advancement of research in regenerative medicine has stimulated a great number of clinical trials, particularly for previously untreatable diseases. This promise has been borne out in the twentieth century with good results obtained with bone-marrow transplantation for oncohematological diseases with the first successful allogeneic bone-marrow transplant by Georges Mathé (1958), and for illnesses other than cancer by Robert Alan Good (1968), and optimized since that time using modern approaches 1,2 .
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Meanwhile, stem cell preclinical studies in ischemic cardiomyopathy have demonstrated heart function improvement with cell-based therapy, and have shown benefits in other tissues such as the spinal cord; thus, it is vital to transfer these treatments to humans in a clinical therapeutic setting [3] [4] [5] [6] .
However, for new therapies, it is necessary to ensure the safety of processes and products in an efficient manner. Toward this aim, therapeutic use of biological products mandates the establishment and use of basic requirements known as Good Tissue
Practices to prevent disease transmission, mix-ups, and cross-contamination, assuring safe cell therapy 7 .
When stem cell therapy is used for oncohematological diseases with bone marrow-derived cell transplantation, the protocol is well established for using fresh bone marrow cells or mononuclear cells from cryopreserved umbilical cord blood for allogeneic transplantation or cryopreserved mononuclear cells from peripheral blood for autologous procedures. All these procedures are conducted without cell cultivation to avoid modified cells. These protocols are rigorously controlled by the International   Society  for  Hematotherapy  and  Graft  Engineering  (ISHAGE, www.celltherapysociety.org).
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As with oncohematological diseases, cell-based regenerative therapy is expected to be useful in nonhematological diseases with cells of adult origin, such as mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs); both cell types are self-renewing populations and have pluripotent capacities to regenerate various tissues: cartilage, bone, muscle tendons, and the nervous system 8, 9 . The three characteristics that define MSCs are a) plastic-adherent growth, b) expansion as undifferentiated MSCs under specific culture conditions with a panel of specific surface antigens, and c) in vitro or in vivo differentiation potential 10 .
MSCs could also be used for transplantation in cell-based therapy, and for this purpose, must be able to expand ex vivo under cultivation. The protocol governs quality control of cells by the FDA, excluding genetically modified cells, and primarily addresses safety concerns with cell differentiation to undesired cell types and potential uncontrolled cell proliferation or tumorigenicity 20 .
Others concerns about the safety of this type of therapy are related to the stability of the product and/or the cell line, specifically, the number of passages/doublings over time, and maintaining desired differentiation properties without karyotypic alterations 21 .
Currently MSC-based therapies were in progress involving cell cultivation; these cells were from various tissues, including hematological, adipose, cornea, conjunctive, skeletal muscle, and oral mucosa 22 .
All of those proceedings impose great costs in translating these therapies to humans and barriers to democratization of advanced therapy approaches. If cell-based therapies could be made more efficient, more people could access their benefits; ideally, the cost of each step would be reduced, without prejudicing the safety of the therapy.
In our laboratory, over the last eight years, we have made morphological observations of undifferentiated MSCs from human bone marrow and adipose tissue up to P5 (not for transplantation use), reviewing and recording a diary of cultured cells using an inverted microscope for the purposes of research academics. We have observed some issues that would be of concern regarding the health of cultured MSCs for potential use in transplantation cell-based therapy. In developing countries, particularly 8 in Brazil where our group is established, we have limited financial resources and at times, we need to answer certain questions without great cost. Why not -do simple things in a simple way‖ 23 ?
With that concept in mind, we chose the Papanicolaou test, known as the Pap smear or cervical smear, a cytological analysis of exfoliated cells from the cervix originally described by George Papanikolaou in 1928 24 . This test is efficient in diagnosing early abnormal changes in the cervical epithelium that could indicate the presence of cervical cancer, and is universally used for screening for cervical cancer in woman 25 . Changes due to technological developments in other areas of science have resulted in significant increases in efficiency since the Pap test was first developed.
The possibility of analyzing cultured MSCs at low cost using the Pap test appears very attractive to avoid additional steps, as a first step why it is a simple and short procedure requiring laboratory equipment available to everyone, in contrast to the more Table 1 shows the results of the flow cytometric analysis for Samples I-VI, as well the viability/apoptosis relationships. The obtained cells were demonstrated to be MSCs from adipose tissue why the cells were marked with antibodies that are in consensus of adipose origin as well the cells were integrity preservation demonstrates by great viability and small apoptosis fraction; all samples have demonstrated the normal profile of undifferentiated adipose derived stem cells (Fig. 1) , the cells were adherents and all 9 samples were capable of differentiation in lipid cells demonstrated by oil Sudan red and bone by alizarin osseous matrix identification, respectively (Fig. 2) . The Pap test for Sample I showed high-grade alterations consistent with genetic instability (Fig. 3,4) , Samples II-V contained atypical cells of undetermined significance (Figs. 5,6 ) and Sample VI comprised normal cells (Fig. 7) .
RESULTS

DISCUSSION
These results demonstrate the potential for using the Pap test as the initial step of a screening methodology to ensure the genetic stability of cultured MSCs. As described by various authors, the difficulty in assuring accuracy in the Pap test is more in the preparation of cervical smears than in the analysis, because it is possible to use rescreening methods for negative results [26] [27] [28] .
It is much easier to obtain a thin and clean smear starting from a cell culture than 
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METHODS
Isolation of adipose tissue-derived MSCs
Human abdominal AT from six healthy female donors was obtained and designated 
Induced differentiation
Differentiated AT-MSCs and their clones were processed as described in Zuk et al.
(2002) 36 . Briefly, the AT-MSCs were washed extensively with sterile PBS to remove contaminating debris and were cultured in induction medium (DMEM/F12 and 10%
FBS supplemented with the growth factors for each cell type: for adipogenic, 0.01 μM 1,25-dihydroxyvitamin D3, 50 μM ascorbate-2-phosphate, 10 mM β-glycerophosphate, and 1% antibiotic; and for osteogenic, 0.5 mM isobutyl-methylxanthine, 1 μM dexamethasone, 10 μM insulin, 200 μM indomethacin, and 1% antibiotic).
Cytology and immunocytochemistry
Differentiated AT-MSCs and their clones were stained for the assays with alizarin for osteogenesis and oil Sudan for adipogenesis.
Papanicolaou staining
The Pap test is based on specific changes in the cytoplasm and/or nucleus of the epithelial cells of the cervix, which can be identified through light microscopy. In this method, the sample cells are placed in a thin and uniform layer on cleaned and degreased glass slides, known as -conventional smears‖. These smears are submersed in a fixative solution (usually absolute ethyl alcohol) and then colored. A combination of two coloring agents is used: a nuclear dye, Harris hematoxylin; and a mixture of two cytoplasmatic dyes, orange G and polychrome mixture (EA51) 37 .
This dye combination highlights cellular aspects that are fundamental in differentiating normal squamous cells of the cervix from low-and high-grade squamous intraepithelial lesions (LSILs and HSILs, respectively) 38 . These aspects include nuclear pigmentation, position, volume, and morphology; membrane regularity and integrity;
and the chromatin arrangement. Other important parameters are the cellular size and shape, and the ratio of the nucleus to the cytoplasm, which is increased in pre-cancerous cells 26, 39 .
In this study, the AT-MSCs were seeded in 25-cm 2 flasks at 5  10 4 /mL, then cultured 
